International Patient Survey (Part 1: Dupuytren Disease)

Chapter

Abstract

This survey of Dupuytren patients is covering 2235 patients and is the largest patient survey so far. It assesses the patients’ perception of the quality of counseling and of treatments. Both appear to exhibit considerable room for improvement. For patients it is important to find a doctor who is able to inform them about all treatment options and to advise which treatment is best for the specific situation of the patient; for doctors it is important to understand the patient’s personal preferences.

All treatments exhibit mixed ratings with fasciectomy, PNF, and collagenase injection rating about equal and radiotherapy slightly better. PNF and radiotherapy are lacking availability in some countries.

According to our results, smoking and family history are causing an earlier onset of Dupuytren disease. We don’t see an effect of moderately drinking alcohol on the onset of Dupuytren disease.

Keywords

Patients’ expectations Counseling Rating therapies Alcohol Smoking Country differences 

References

  1. Anthony SG, Lozano-Calderon SA, Simmons BP, Jupiter JB (2008) Gender ratio of Dupuytren’s disease in the modern U.S. Population. Hand 3(2):87–90PubMedCrossRefGoogle Scholar
  2. Becker K et al (2014) The importance of genetic susceptibility in Dupuytren’s disease. Clin Genet 87(5):483–487PubMedCrossRefGoogle Scholar
  3. Carboni G, Orton H, Wach W (2015) The patient’s view and the international Dupuytren society. In: Warwick D (ed) Dupuytren’s disease – FESSH instructional course 2015. Edizione Medico Scientifiche, Turin, pp 57–64Google Scholar
  4. Dahlin LB, Bainbridge C et al (2013) Dupuytren’s disease presentation, referral pathways and resource utilisation in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 67(3):261–270PubMedCrossRefGoogle Scholar
  5. Descatha A, Carton M, Mediouni Z et al (2014) Association among work exposure, alcohol intake, smoking and Dupuytren’s disease in a large cohort study (GAZEL). BMJ Open 4:e004214PubMedPubMedCentralCrossRefGoogle Scholar
  6. Dias J, Braybrooke J (2006) Dupuytren’s contracture: an audit of the outcome of surgery. J Hand Surg 31B:514–521CrossRefGoogle Scholar
  7. Dias J, Bainbridge C, Leclercq C et al (2013) Surgical management of Dupuytren’s contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 67(3):271–281PubMedCrossRefGoogle Scholar
  8. DiBenedetti DB, Nguyen D, Zografos L et al (2011) A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv. Urol. ID 282503.Google Scholar
  9. Dolmans G, Hennies H (2012) The genetic basis of Dupuytren’s disease: an introduction. In: Eaton C (ed) Dupuytren’s disease and related hyperproliferative disorders. Springer, Heidelberg/New York, pp 87–91CrossRefGoogle Scholar
  10. Dolmans GH, de Bock GH, Werker PM (2012) Dupuytren diathesis and genetic risk. J Hand Surg Am 37(10):2106–2111PubMedCrossRefGoogle Scholar
  11. Eaton C (2016a) The next stage of clinical Dupuytren research: biomarkers and chronic disease research tools. In: Werker PMN, Dias J, Eaton C, Reichert B, Wach W (eds) Dupuytren Disease and Related Diseases – The Cutting Edge. Springer, Cham, pp 391–407Google Scholar
  12. Eaton C (2016b) IDDB: an international research database of the Dupuytren foundation. In: Werker PMN, Dias J, Eaton C, Reichert B, Wach W (eds) Dupuytren Disease and Related Diseases – The Cutting Edge. Springer, Cham, pp 427–435Google Scholar
  13. Lanting R et al (2013) Prevalence of Dupuytren disease in The Netherlands. J Plast Reconstr Surg 132:394–403CrossRefGoogle Scholar
  14. Loos B, Puschkin V, Horch RE (2007) 50 years experience with Dupuytren’s contracture in the Erlangen University Hospital – a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord 8:60PubMedPubMedCentralCrossRefGoogle Scholar
  15. Mikkelsen OA (1972) The prevalence of Dupuytren’s disease in Norway. Acta Chir Scand 138:695–700PubMedGoogle Scholar
  16. Ross DC (1999) Epidemiology of Dupuytren’s disease. Hand Clin 15(1):53–62PubMedGoogle Scholar
  17. Seegenschmiedt MH, Keilholz L, Wielpütz M et al (2012) Long-term outcome of radiotherapy for early stage Dupuytren’s disease: a phase III clinical study. In: Eaton C et al (eds) Dupuytren’s disease and related hyperproliferative disorders. Springer, Heidelberg/New York, pp 349–371CrossRefGoogle Scholar
  18. Schurer A, Manley G, Wach W (2016) International patient survey (Part 2: Ledderhose disease). In: Werker PMN, Dias J, Eaton C, Reichert B, Wach W (eds) Dupuytren Disease and Related Diseases – The Cutting Edge. Springer, Cham, pp 371–379Google Scholar
  19. Valente EG, Vernet D, Ferrini MG et al (2003) L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide 9(4):229–244PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.International Dupuytren Society83236Germany
  2. 2.British Dupuytren’s SocietyWiganUK

Personalised recommendations